Literature DB >> 7651726

Cloning and characterization of murine p16INK4a and p15INK4b genes.

D E Quelle1, R A Ashmun, G J Hannon, P A Rehberger, D Trono, K H Richter, C Walker, D Beach, C J Sherr, M Serrano.   

Abstract

Progression through the G1 phase of the cell cycle is regulated in part by the D-type cyclin-dependent kinases, cdk4 and cdk6. Genes encoding two specific inhibitors of these kinases, human p16(INK4a/MTS1) and p15(INK4b/MTS2), map to a region of common cytogenetic abnormalities on chromosome 9p21. The murine cognates of these genes were isolated and identified as mouse p16INK4a and p15INK4b based on their homology to their human counterparts and their selective transcriptional induction by SV40T-antigen and TGF-beta, respectively. Both genes map to position C3-C6 on mouse chromosome 4, in a region syntenic with human chromosome 9p. Amplification of polyadenylated mRNA by polymerase chain reactions revealed no expression of mouse p16INK4a in many normal tissues, whereas p15INK4b was expressed ubiquitously. Like human p16INK4a, mouse p16INK4a binds specifically to cdk4 and cdk6 in vitro and inhibits the phosphorylation of the retinoblastoma protein, pRb, by each of these cyclin D-dependent kinases. In mouse MEL erythroleukemia cells, p16INK4a associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. Expression vectors encoding human or mouse p16INK4a caused G1 phase arrest in NIH3T3 fibroblasts, and cyclin D1- and cdk4-dependent pRb kinase activities were inhibited in the p16INK4a-arrested cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651726

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

Review 1.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

2.  An astroblastoma case associated with loss of heterozygosity on chromosome 9p.

Authors:  Nobuhiro Hata; Tadahisa Shono; Koji Yoshimoto; Masahiro Mizoguchi; Tadao Kawamura; Shinji Nagata; Kenichi Matsumoto; Kenshi Hayashi; Toru Iwaki; Tomio Sasaki
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

3.  Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.

Authors:  K Alevizopoulos; J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

Review 4.  Cardiac myocyte cell cycle control in development, disease, and regeneration.

Authors:  Preeti Ahuja; Patima Sdek; W Robb MacLellan
Journal:  Physiol Rev       Date:  2007-04       Impact factor: 37.312

Review 5.  Negative regulators in homeostasis of naïve peripheral T cells.

Authors:  Jaime F Modiano; Lisa D S Johnson; Donald Bellgrau
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 6.  Nucleolar adaptation in human cancer.

Authors:  Leonard B Maggi; Jason D Weber
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

7.  Inhibition of cell proliferation by the Mad1 transcriptional repressor.

Authors:  M F Roussel; R A Ashmun; C J Sherr; R N Eisenman; D E Ayer
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

8.  Frequent aberrant methylation of p16INK4a in primary rat lung tumors.

Authors:  D S Swafford; S K Middleton; W A Palmisano; K J Nikula; J Tesfaigzi; S B Baylin; J G Herman; S A Belinsky
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

9.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

10.  Identification of candidate lung cancer susceptibility genes in mouse using oligonucleotide arrays.

Authors:  W J Lemon; H Bernert; H Sun; Y Wang; M You
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.